Efficacy and tolerability of a fixed-dose combination of metoprolol extended releaseAmlodipine in patients with mild-to-moderate hypertension: A randomized, parallel-group, multicentre comparison with losartan plus amlodipine

Clinical Drug Investigation

Volumn 30, Issue 2, 2010, Pages 123-131

  Pareek, Anil ^a   Chandurkar, Nitin B ^a   Sharma, Ravishankar ^b   Tiwari, Dharmendra ^c   Gupta, Bhagwan S ^d  

^a Ipca Laboratories Ltd   (India)

^b NSCB MEDICAL COLLEGE   (India)

^c G R MEDICAL COLLEGE   (India)

^d SMS MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS LOSARTAN; AMLODIPINE PLUS METOPROLOL; ANTIHYPERTENSIVE AGENT; CALCHECK; LOSANORM; UNCLASSIFIED DRUG; VINICOR AM;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; ELECTROLYTES; FEMALE; HEART RATE; HUMANS; LOSARTAN; MALE; METOPROLOL; MIDDLE AGED; YOUNG ADULT;

EID: 75149193090     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11531770-000000000-00000     Document Type: Article

References (20)

1. Sytkowski PA, D'Agostino RB, Belanger AJ, et al. Secular trends in long term sustained hypertension, long term treatment and cardiovascular mortality: the Framingham Heart Study 1950 to 1990. Circulation 1996; 93: 697-703
2. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335 (8692): 765-774
3. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006; 29 (Suppl.): S1-105
4. Chobanian AV, Bakris GL, Black HR, et al., National Heart, Lung and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572
5. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053
6. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992
7. Guidelines Subcommittee: 1999 World Health Organization- International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183
8. Saito I, Saruta T, ADVANCE-Combi study group. Controlled- release nifedipine and valsartan combination therapy in patients with essential hypertension: the Adalat CR and valsartan cost-effectiveness combination (ADVANCECombi) study. Hypertens Res 2006; 29: 789-796
9. Haria M, Plosker GL, Markham A. Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension. Drugs 2000 Jan; 59 (1): 141-157
10. Menard J. Clinical assessment of combination therapy development. Blood Press 1993; 2 Suppl. 1: 5-9
11. Maclean D, Mitchell ET, Irvine RL, et al. Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension. Br J Clin Pharm 1990; 29: 455-463
12. Brown MJ, Cruickshank JK, MacGregor GA, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003; 17: 81-86
13. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2. Short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-838
14. Sica DA. Fixed-dose combination of antihypertensive drugs: do they have a role in rational therapy? Drugs 1994; 48: 16-24
15. Kohlman O, Oigman W, Mion D, et al. The "LOTHAR" study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension. Arg Bras Cardiol 2006; 86 (1): 39-51
16. Neutel JM, Littlejohn TW, Chrysant SG, et al., on behalf of the Telmisartan Study Group. Telmisartan/ hydrochlorothiazide in comparison with losartan/ hydrochlorothiazide in managing patients with mild-tomoderate hypertension. Hypertens Res 2005; 28: 555-563
17. Lacourciere Y, Gil-Extremera B, Mueller O, et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57 (4): 273-279
18. Saruta T, Ogihara T, Matsuoka H, et al. Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res 2007; 30: 729-739 (Pubitemid 47517107)
19. Shen F, Xie H, Ling G, et al. Synergistic effects of atenolol and amlodipine for lowering and stabilizing blood pressure in 2K1C renovascular hypertensive rats. Acta Pharmacologica Sinica 2005; 26: 1303-1308
20. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a metaanalysis. Evid Based Med 2008 Feb; 13 (1): 18